FORM 8.3IRISH TAKEOVER PANELDISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE1\. KEY INFORMATIONName of person dealing (Note 1)State Street Global Advisors & Affiliates Company dealt inAon plc Class of relevant security to which the dealings being disclosed relate (Note 2)US$0.01 ordinary shares Date of dealing19th October 2020 2\. INTERESTS AND SHORT POSITIONS(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) LongShort Number(%)Number(%) (1) Relevant securities8,932,612 3.89975% (2) Derivatives (other than options)N/A (3) Options and agreements to purchase/sellN/A Total8,932,612 3.89975% (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)Class of relevant security:LongShort Number(%)Number(%) (1) Relevant securitiesN/A (2) Derivatives (other than options)N/A (3) Options and agreements to purchase/sellN/A TotalN/A 3\. DEALINGS (Note 4)(a) Purchases and salesPurchase/saleNumber of relevant securitiesPrice per unit (Note 5) Purchase4,448209.19 Purchase3,811209.19 Purchase42209.19 Purchase48209.19 Purchase21209.19 Sale5,282209.19 Sale10,094209.19 Sale48209.19 (b) Derivatives transactions (other than options transactions)Product name, e.g. CFDNature of transaction (Note 6)Number of relevant securities (Note 7)Price per unit (Note 5) N/A (c) Options transactions in respect of existing relevant securities(i) Writing, selling, purchasing or varyingProduct name, e.g. call optionWriting, selling, purchasing varying etc.Number of securities to which the option relates (Note 7)Exercise priceType, e.g. American, European etc.Expiry dateOption money paid/received per unit (Note 5) N/A (ii) ExercisingProduct name, e.g. call optionNumber of securitiesExercise price per unit (Note 5) N/A (d) Other dealings (including transactions in respect of new securities) (Note 4)Nature of transaction (Note 8)DetailsPrice per unit (if applicable) (Note 5) N/A 4\. OTHER INFORMATIONAgreements, arrangements or understandings relating to options or derivativesFull details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. N/A Is a Supplemental Form 8 attached? (Note 9)NO Date of disclosure20th October 2020 Contact nameLionel Colaco Telephone number 020 33956098 If a connected EFM, name of offeree/offeror with which connectedN/A If a connected EFM, state nature of connection (Note 10)N/A
AM Best has assigned a Preliminary Credit Assessment (PCA) to Vantage Risk Ltd. (Vantage) (Bermuda) with a Financial Strength Assessment of A- pca (Excellent) and a Long-Term Issuer Credit Assessment of "a-" pca. The outlook assigned to these PCAs is stable.
Essential Utilities Inc. (NYSE:WTRG) published its 2019 Environmental, Social, and Governance or ESG report today. The report is published as an interactive microsite and is available at esg.essential.co. It follows a number of leading reporting frameworks, including those set out by the Sustainability Accounting Standards Board (SASB), the Task Force on Climate-related Financial Disclosures (TCFD) and also highlights how our corporate efforts help society achieve some of the United Nations Sustainable Development Goals (UN SDGs).
The dollar index declined 0.31% and was on track for its second day of declines as House Speaker Nancy Pelosi set the end of the day as a deadline for negotiations over a coronavirus aid package. As polls have widened in favor of Democratic presidential candidate Joe Biden, foreign exchange volumes have been dropping, he added. While markets are confident a win by Biden would lead to more fiscal stimulus, potentially weakening the dollar, investors are also wary of a potentially contested election result that might boost the safe-haven appeal of the greenback.
While almost 95 percent of cybersecurity issues can be traced back to human error, such as accidentally clicking on a malicious link, most governments have not invested enough to educate their citizens about the risks according to a new report from the Oliver Wyman Forum. Cyber literacy, along with financial literacy, is a new 21st century priority for governments, educational institutions, and businesses.
Percepio launches Tracealyzer 4.4 with support for embedded Linux, enabling developers to speed debugging with improved visual trace diagnostics.
Summary Market Analysis and Forecast Models are built to visualize quantitative market trends within a specific therapeutic area. Each model is segmented further to provide granularity and pertinent data for respective markets.New York, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Dental Lasers (Dental Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)" - https://www.reportlinker.com/p05978040/?utm_source=GNW To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, and company share analysis.We provide epidemiology based indications with procedure volumes. All the models are color-coded and fully-sourced, moreover, analyst comments with qualitative insight offer context for quantitative data. Robust methodologies and sources enable our models to provide extensive and accurate overviews of markets.Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. The analyst conducts thousands of interviews with demand side participants, most of them are physicians, surgeons, and specialists within their therapeutic areas. In addition, real world data sources are leveraged to determine market trends, these include government procedure databases, hospital purchasing databases, and proprietary online databases. The model discusses in detail the impact of COVID-19 on dental lasers market for the year 2020 and beyond.Dental lasers are categorized to be used in varying dental procedures such as gum surgery, cavity treatment, and other oral indications. Lasers utilize gas, semiconductors or specific crystals to alter or remove tissue.Laser dentistry is an innovative step forward within the dental market. Gingivitis and Periodontitis indications can be treated with dental lasers. Lasers can be implemented across all dental disciplines such as: restorative dentistry, surgical applications, oral disease, periodontics, endodontics, and biostimulation. Currently marketed Dental Lasers market and evolving competitive landscape - \- Insightful review of the key industry trends. \- Annualized total Dental Lasers market revenue by segment and market outlooks from 2015-2030. \- Granular data on total procedures, units, average selling prices and market values by segment. Scope This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for - \- CMO executives who must have deep understanding of the Dental Lasers marketplace to make strategic planning and investment decisions. \- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management. \- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets. Reasons to Buy The model will enable you to - \- Understand the impact of COVID-19 on Dental Lasers market. \- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. \- Develop business strategies by understanding the trends shaping and driving Dental Lasers market. \- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Dental Lasers market in the future. \- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders. \- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. \- Track device sales in the global and country-specific Dental Lasers market from 2015-2030. \- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Read the full report: https://www.reportlinker.com/p05978040/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that purchased or acquired the securities of Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) between February 11, 2020 and August 10, 2020 (the “Class Period”). The lawsuit filed in the United States District Court for the Middle District of North Carolina alleges violations of the Securities Exchange Act of 1934. If you purchased FENC securities, and/or would like to discuss your legal rights and options please visit Fennec Shareholder Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Fennec’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the manufacturing facilities for PEDMARK, the Company’s sole product candidate, did not comply with current good manufacturing practices; (2) that, as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.On August 11, 2020, before the market opened, Fennec disclosed that it had received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the Company’s New Drug Application (“NDA”) for PEDMARK. According to the CRL, “after recent completion of a pre-approval inspection of the manufacturing facility of [Fennec’s] drug product manufacturer, the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that are required to be resolved prior to the approval of PEDMARK.”On this news, the Company’s share price fell $3.51, or 34%, to close at $6.66 per share on August 11, 2020, thereby injuring investors.If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.If you purchased Fennec securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/fennecpharmaceuticalsinc-fenc-shareholder-class-action-lawsuit-stock-fraud-305/apply or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.ATTORNEY ADVERTISING. © 2020 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.Contact Information Matthew E. Guarnero Bernstein Liebhard LLP https://www.bernlieb.com (877) 779-1414 MGuarnero@bernlieb.com
3M launched the new 3M™ Visual Attention Software (VAS) plugin for Adobe® Photoshop®, a "visual spellcheck" to aid designers through powerful AI.
The "Europe Flatbread Market by Product Type, Distribution Channel and Nature: Europe Opportunity Analysis and Industry Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.
Los Angeles, CA, Oct. 20, 2020 (GLOBE NEWSWIRE) -- KRONOS ADVANCED TECHNOLOGIES, INC., (OTC MARKETS: KNOS) ("KNOS" or the "Company"), a revenue-generating, product development and production company that has significantly changed the way air is moved, filtered and sterilized encourages consumers to utilize the flexible spending account balances as the year-end deadline approaches. FSA's and HAS’s are pre-tax accounts consumers can use to pay for healthcare related expenses.The passage of the $2 trillion+ coronavirus (COVID-19) relief bill in March 2020 included essential steps forward in helping Americans protect the health and quality of life of their families by introducing innovative ways for consumers to seek medical care, to be able to visit their doctors remotely during times of increased demand and creating even more value for the millions of Americans with Flexible Spending Accounts (FSAs) and Health Savings Accounts (HSAs). FSA/HSA account users can use these accounts to purchase many new and necessary healthcare-related products and services, including air purifiers, especially for asthma sufferers.The EPA, CDC, American Lung Association coordinated approach on asthma promotes scientific understanding of environmental asthma triggers and ways to manage asthma in community settings through research, education, and outreach. With federal, state, and local partners, EPA is building the nation's capacity to control asthma and manage exposure to indoor and outdoor pollutants linked to asthma. In particular, there are many pollutants found indoors that can trigger asthma attacks. Smart, advanced air purifiers that remove small particles may alleviate asthma symptoms.Kronos Air Purifiers eliminate and remove allergens, bacteria, viruses down to 14,6 nm. To learn more about Kronos Air Purifiers please visit our shopping portal: https://www.1800safeair.comThe December 31 deadline is quickly approaching. Millions of flexible spending account (FSA) holders are at risk of losing their money. Air purifiers are eligible for reimbursement with flexible spending accounts (FSA), health savings accounts (HSA), and health reimbursement accounts (HRA) with a Letter of Medical Necessity (LMN). There are many eligible expenses for tax-free purchase with a Health Savings Account (HSA), Flexible Spending Account (FSA), and Health Reimbursement Arrangement (HRA)—including prescriptions, doctor's office copays, health insurance deductibles, and coinsurance.Kronos has prepared a sample of the Letter of Medical Necessity and detailed steps on our "How to pay for your KRONOS Air purifier with your FSA" guide. Interested consumers are invited to email the Company via Info@kronosati.co for more information.About Kronos Advanced Technologies, Inc.Kronos Advanced Technologies, Inc. began operations in 2002 as a product development company that invented and significantly changed the way air is moved, filtered, and sterilized. Historically, Kronos has focused on developing, marketing, and selling the Company's proprietary air movement and purification technology. Serving the Indoor Air Quality (IAQ) market, Kronos technology uses state-of-the-art high voltage patented processes without the use of traditional porous HEPA filters. Kronos-based products move air silently, filter, sterilize, and purify the air while dramatically reducing energy consumption to half of a 60-watt light bulb. Kronos devices can be variable in shape or size, and, therefore, have the potential to be scaled-down for air purification in cars or scaled-up in size for industrial and hazardous gas destruction. The technology is currently being implemented in multiple standalone products for businesses, homes, and vehicles of all types -to move, sterilize and filter air, including removing allergens down to 14.6 nanometers, passing through our patented technology -replacing expensive outdated passive HEPA and other filtration type systems. There are broad ranges of additional markets for standalone and embedded Kronos CORE technology-based devices. Examples of immediately addressable markets include schools, universities, healthcare facilities, operating rooms, manufacturing clean rooms, and the cabins of automobiles and commercial aircraft. Recently, the Company filed for a provisional patent involving an innovative protective face mask with antimicrobial and anti-cellphone radiation protection features. The Company is planning to file additional patents to improve its existing technology as well as enter into new market segments but will continue to market air purifiers and other consumer products. The Company is an exclusive distributor and licensee of the latest generation of air purifiers based on the Company's CORE technologies. The Company markets its products as Airdog® and KRONOS® brands. Company offices are located in Los Angeles, California.Shopping portal: https://www.1800safeair.comFollow KNOS on Twitter: https://twitter.com/kronosatiFollow KNOS on Facebook: https://www.facebook.com/kronosatiFollow KNOS on Instagram: https://www.instagram.com/kronos_ati/Follow KNOS on Youtube: https://www.youtube.com/channel/UCdtrQDt1R26Ulh8v-S-EpJgContact us via: firstname.lastname@example.org or visit https://www.kronosati.co or https://www.1800SAFEAIR.comForward-looking statements:Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the OTC Markets at OTCMarkets.com. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products.The forward-looking statements included in this press release represent the Company's views as of the date of this press release, and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.SOURCE: KRONOS ADVANCED TECHNOLOGIES, IncPhone inquiries: 1-800-SAFE-AIR (option 4)
The "Global Batch Control Systems Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
President Donald Trump called Tuesday on the US attorney general to investigate his "criminal" Democratic opponent Joe Biden, as he headed to a rally in the key state of Pennsylvania two weeks before election day.
Article Details GigaGen’s Affinity Maturation Approach for the Optimization of Monoclonal Antibody Drug Candidates Discovered via its Surge PlatformSOUTH SAN FRANCISCO, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today publication of a peer-reviewed article titled, “Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR,” in the peer-reviewed journal mAbs. The publication is available online here. GigaGen’s newly published data details the technical foundation of its approach for the affinity maturation of monoclonal antibodies discovered via its leading single-cell microfluidic technology platform, Surge. Affinity maturation is commonly used for antibody optimization when developing new drugs. The company is leveraging this technology platform for the development of monoclonal antibodies with unique binding and affinity profiles against selected oncology targets.David Johnson, Ph.D., MBA, co-founder and chief executive officer of GigaGen, commented, “Often, antibodies need to be further engineered through ‘affinity maturation’ to achieve the appropriate affinities and kinetics that translate into in vivo efficacy. While this process can be important for antibody drug development, there are no universally accepted protocols for efficient and high-performance antibody affinity maturation. Our study is one of the most thorough evaluations of affinity maturation methods ever published. We have used knowledge from our work to develop novel antibody therapeutics with unique profiles against selected oncology targets, such as CTLA-4, with the potential to result in enhanced efficacy and safety profiles versus current antibody drug alternatives.”Study highlights * GigaGen’s antibody affinity maturation approach includes a novel mutagenesis strategy, which enables combinatorial mutagenesis of individual amino acids in handpicked regions of a target gene, which can be leveraged to generate proteins with enhanced functionalities. * Critical to the workflow is the incorporation of long-read-next generation sequencing, which allows GigaGen to readily analyze the DNA sequence across thousands of mutants, creating mutational maps and comparisons not readily done using traditional sequencing approaches. * GigaGen’s approach also enables functional examination of library-derived scFv antibodies and their corresponding full-length antibodies. About Surge GigaGen’s single-cell technology platform, Surge, is a unique combination of single-cell emulsion droplet microfluidics technology, genomics and protein library engineering, which significantly increases the productivity and speed of antibody drug discovery. Surge captures and recreates complete antibody repertoires as recombinant antibody libraries, encompassing nearly 100% of the diversity within natural antibody libraries. Additionally, it enables massively parallel screening of millions of antibody libraries while uniquely maintaining the native pairing of the antibody light and heavy chains, crucial for the development of antibodies with optimal function and high sensitivity and specificity. Surge replaces conventional drug discovery technologies such as hybridomas and phage display, enabling discovery of a wide spectrum of drug candidates, including rare antibodies with potentially unique profiles.About GigaGen GigaGen is advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers by leveraging industry-leading, single-cell technologies. Our technology uniquely captures and recreates complete immune repertoires as functional antibody libraries. This approach has enabled the creation of the first recombinant polyclonal immunoglobulin therapies, which overcome current limitations of plasma-based products. GigaGen’s technology has also filled a pipeline of monoclonal antibodies with unique properties against known and novel oncology targets with the potential to translate into therapies with improved efficacy and safety profiles.Media Contact Monica Rouco Molina, Ph.D. LifeSci Communications +1-929-469-3850 email@example.com
Palladio Biosciences, Inc. (Palladio), a privately-owned, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney, announced today the results of a study that investigated the use of lixivaptan in a patient with autosomal dominant polycystic kidney disease (ADPKD) who could not tolerate a different vasopressin V2 receptor antagonist, tolvaptan. The presentation will be made as an ePoster during the American Society of Nephrology’s Kidney Week 2020. The conference is being held as a fully digital meeting, October 22-25.
In this article we are going to estimate the intrinsic value of Northern Oil and Gas, Inc. (NYSEMKT:NOG) by estimating...
Intel, best known for making computer processors used in desktops and laptops, has been trying to focus more on its strengths, including the Optane memory business, which is smaller but lucrative as it taps more advanced technology. Exiting the NAND chips business will also help the chipmaker fend off the impact on profit from being in a cut-throat commodity memory market, where prices cycle through booms and busts. Cowen and Co analysts said the deal was critical for Intel as it would lessen "the product and manufacturing variables" required to get its core PC/server processor businesses back on track.
TravelCenters of America Inc., (Nasdaq: TA) nationwide operator of the TA, Petro Stopping Centers and TA Express travel center network, has teamed up with Mobil Delvac heavy-duty diesel engine oil to donate $50,000 to Folds of Honor, an organization providing educational scholarships to the spouses and children of America’s fallen and disabled service members. This is the fourth year in a row TA and Mobil Delvac diesel engine oil have come together to support the organization on behalf of its customers, and as a thank you for their loyalty.
"It's going to be pretty strong earnings across the board,” said Deutsche Bank industry analyst Emmanuel Rosner, adding he expected all suppliers and carmakers to beat current forecasts. In China too, General Motors Co <GM.N> and Ford Motor Co <F.N> are recovering, registering double-digit sales growth for the quarter. For GM, 12% year-on-year growth in July-September, marked the Detroit automaker’s first quarterly sales improvement in two years in the world's biggest market.